884: Phase I Clinical Study of Anti-Apoptosis Protein, Survivin-Derived Peptide Vaccine Therapy for Patients with Advanced or Recurrent Urothelial Cancer | Zendy

AI Assistant Blog Pricing

884: Phase I Clinical Study of Anti-Apoptosis Protein, Survivin-Derived Peptide Vaccine Therapy for Patients with Advanced or Recurrent Urothelial Cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.